Granit Veseli, MD
Clinical Cardiac Electrophysiology · Norwalk, CTNPI 1396036091
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $15,300 of the $24,955 with a category attached, or 61.3%. 29 manufacturers reported payments, led by Medtronic at 36.4% of the total. Reporting peaked in 2024 at $10,013 and has fallen 88.3% since, to $1,175 in 2025.
Across 251 payments — averaging $99.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$9K
- Abbott$6K
- Biotronik Inc.$4K
- Boston Scientific$3K
- Biosense Webster, Inc.$720
- Cvrx, Inc.$631
- plus $2K from 23 others
What the payments were for
- Travel & lodging$15,30061%
- Food & beverage$9,34137%
- Education$3151%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 68 | $9,074 |
| Abbott | 29 | $5,680 |
| Biotronik Inc. | 29 | $4,070 |
| Boston Scientific | 40 | $3,225 |
| Biosense Webster, Inc. | 12 | $720 |
| Cvrx, Inc. | 5 | $631 |
| Amgen | 11 | $221 |
| Johnson & Johnson | 10 | $186 |
| Sanofi-aventis U.S. LLC | 7 | $168 |
| Boehringer Ingelheim | 5 | $126 |
| Philips North America LLC | 1 | $113 |
| Novo Nordisk | 4 | $89 |
| Amarin Pharma, Inc. | 4 | $83 |
| Regeneron Healthcare Solutions, Inc. | 3 | $78 |
| Bardy Diagnostics, Inc. | 2 | $73 |
| Tactile Systems Technology Inc | 2 | $51 |
| Irhythm Technologies, Inc. | 2 | $51 |
| AstraZeneca | 3 | $48 |
| Merck | 2 | $39 |
| Pfizer | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Baxter Healthcare | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Bayer | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$4,122
- GENERAL - THERAPIES$1,505
- Micra$1,012
- Acticor 7 VR-T DX$827
- DIAMONDTEMP BIDIRECTIONAL ABLATION CATHETER$779
- AMPLATZER AMULET$726
- SelectSecure$625
- Barostim Neo System$523
- BioMonitor$457
- SQ RX PULSE GENERATOR$393
- Carto 3 System$236
- AMPLATZER TORQVUE 45 X 45$199
- Solia$175
- Rivacor$175
- Acticor$175
- Edora$175
- JOT DX$161
- QDOT MICRO Catheter$148
- Rhythmia Mapping System$145
- LINQ II$145
How this compares
$24,955 in reported general payments places this provider in the 60th percentile of 47 clinical cardiac electrophysiology providers in Connecticut.
See all clinical cardiac electrophysiology providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 63 | $66,948 |
| XareltoRivaroxaban | 46 | $51,366 |
| MultaqDronedarone Hcl | 31 | $38,310 |
| Dofetilide | 51 | $25,897 |
| Amiodarone Hcl | 54 | $2,284 |
| Metoprolol Succinate | 97 | $1,621 |
| Flecainide Acetate | 15 | $522 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 12 | $366 |
| SotalolSotalol Hcl | 11 | $249 |
| Metoprolol Tartrate | 12 | $147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $36 | $66,94863 claims |
| Johnson & JohnsonXarelto | $186 | $51,36646 claims |
| Sanofi-aventis U.S. LLCMultaq | $168 | $38,31031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 47 clinical cardiac electrophysiology providers in Connecticut.
Other clinical cardiac electrophysiology in Norwalk
- John NovellaNorwalk$4K
- Teresa MenendezNorwalk$2K
- Joseph Dell OrfanoHartford$160K
- Paras BhattNorwich$139K
- Steven ZweibelHartford$125K
- Murali ChiravuriFairfield$101K
- James FreemanNew Haven$87K
- Jude ClancyMiddletown$84K
- Joseph TianoTrumbull$70K
- Michael PittaroStamford$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.